Medical devices, healthcare technology and the business of care
510(k) clearance · K254210

REBOHIL (BGM-1, BGM-2, BGM-3, BGM-4, BGM-5)

Hyundai Bioland Co., Ltd. · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONK254210

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 09/25/2026 for REBOHIL (BGM-1, BGM-2, BGM-3, BGM-4, BGM-5), submitted by Hyundai Bioland Co., Ltd. of Cheongju-Si, Republic of Korea, under 510(k) number K254210. The application was received 12/29/2025 and reviewed as a traditional 510(k) by the Dental panel; it was not reviewed by a third party, not a combination product, and no predetermined change control plan was authorized. SESE means the device was cleared for marketing, not approved under a PMA.

The listed classification is Bone Grafting Material, Animal Source, regulation 872.3930, product code NPM, in the Dental medical specialty. The record identifies five model designations (BGM-1 through BGM-5) but does not state what distinguishes them, what the device is composed of, or which predicate device the equivalence finding rests on. The public summary field is empty, so the indications for use, materials, and any supporting performance data remain unknown from this source.

Readers should treat the clearance as a regulatory status record only. No clinical, safety, or comparative effectiveness conclusion follows from the decision, and the absence of a summary in the retrieved page limits any assessment of the basis for the equivalence determination.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Dental
Decision date
Sep 25, 2026
FDA decision documents: 510(k) Premarket Notification - FDA

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K254210
Regulatory pathway
510(k) premarket notification
Product code
NPM
Decision code
SESE
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Bone Grafting Material, Animal Source.

Product code
NPM
FDA device class
2

FDA decision timeline

  1. K254210 received

    Application receipt date recorded by FDA.

  2. K254210 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code NPM

Product / regulatory recordCompanyPathwayDecision dateSource
Wishbone SA510(k) clearanceOct 9, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Hyundai Bioland Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Cheongju-Si

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records